Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA

Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Angeli, Michele Fabrizio, Francesco Donati, Sebastiano Toniolo, Chiara Chiti, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Ilenia Magnani, Gianmarco Iannopollo, Paola Rucci, Gianni Casella, Nazzareno Galiè, Carmine Pizzi, Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Angeli, Michele Fabrizio, Francesco Donati, Sebastiano Toniolo, Chiara Chiti, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Ilenia Magnani, Gianmarco Iannopollo, Paola Rucci, Gianni Casella, Nazzareno Galiè, Carmine Pizzi

Abstract

Background: The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking. Recently, we demonstrated that admission stress-hyperglycemia (aHGL) was associated with a larger infarct size and inflammatory response in MIOCA, while no differences were observed in MINOCA. We aim to investigate the impact of aHGL on short and long-term outcomes in MIOCA and MINOCA patients.

Methods: Multicenter, population-based, cohort study of the prospective registry, designed to evaluate the prognostic information of patients admitted with acute myocardial infarction to S. Orsola-Malpighi and Maggiore Hospitals of Bologna metropolitan area. Among 2704 patients enrolled from 2016 to 2020, 2431 patients were classified according to the presence of aHGL (defined as admission glucose level ≥ 140 mg/dL) and AMI phenotype (MIOCA/MINOCA): no-aHGL (n = 1321), aHGL (n = 877) in MIOCA and no-aHGL (n = 195), aHGL (n = 38) in MINOCA. Short-term outcomes included in-hospital death and arrhythmias. Long-term outcomes were all-cause and cardiovascular mortality.

Results: aHGL was associated with a higher in-hospital arrhythmic burden in MINOCA and MIOCA, with increased in-hospital mortality only in MIOCA. After adjusting for age, gender, hypertension, Killip class and AMI phenotypes, aHGL predicted higher in-hospital mortality in non-diabetic (HR = 4.2; 95% CI 1.9-9.5, p = 0.001) and diabetic patients (HR = 3.5, 95% CI 1.5-8.2, p = 0.003). During long-term follow-up, aHGL was associated with 2-fold increased mortality in MIOCA and a 4-fold increase in MINOCA (p = 0.032 and p = 0.016). Kaplan Meier 3-year survival of non-hyperglycemic patients was greater than in aHGL patients for both groups. No differences in survival were found between hyperglycemic MIOCA and MINOCA patients. After adjusting for age, gender, hypertension, smoking, LVEF, STEMI/NSTEMI and AMI phenotypes (MIOCA/MINOCA), aHGL predicted higher long-term mortality.

Conclusions: aHGL was identified as a strong predictor of adverse short- and long-term outcomes in both MIOCA and MINOCA, regardless of diabetes. aHGL should be considered a high-risk prognostic marker in all AMI patients, independently of the underlying coronary anatomy. Trial registration data were part of the ongoing observational study AMIPE: Acute Myocardial Infarction, Prognostic and Therapeutic Evaluation. ClinicalTrials.gov Identifier: NCT03883711.

Keywords: Acute myocardial infarction; Long-term prognosis; MINOCA; MIOCA; Short-term prognosis; Stress-hyperglycemia.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves in AMI patients with and without hyperglycemia. A All-cause mortality. Significant pairwise differences were found for MINOCA with and without hyperglycemia (p < 0.01), MIOCA with and without hyperglycemia (p < 0.001); MIOCA with hyperglycemia and MINOCA without hyperglycemia, (p < 0.05), MINOCA with hyperglycemia and MIOCA without hyperglycemia (p < 0.001), B cardiovascular mortality MIOCA with hyperglycemia and MINOCA without hyperglycemia (p = 0.011), MINOCA with hyperglycemia and MIOCA without hyperglycemia (p < 0.01), MINOCA with and without hyperglycemia (p = 0.0011), MIOCA with and without hyperglycemia (p < 0.001)
Fig. 2
Fig. 2
Predicted probability of all-cause death per groups according to admission blood glucose levels presented as continuous variable. MIOCA: red curve; MINOCA: blue curve

References

    1. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–778. doi: 10.1016/S0140-6736(99)08415-9.
    1. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117:1610–1619. doi: 10.1161/CIRCULATIONAHA.107.188629.
    1. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16–38. doi: 10.1210/jc.2011-2098.
    1. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078–3086. doi: 10.1161/CIRCULATIONAHA.104.517839.
    1. American Diabetes Association 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S73–S84. doi: 10.2337/dc21-S006.
    1. Cid-Alvarez B, Gude F, Cadarso-Suarez C, et al. Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: nonlinearity of hazard ratios and time-dependent comparison. Am Heart J. 2009;158:989–997. doi: 10.1016/j.ahj.2009.10.004.
    1. Singh K, Hibbert B, Singh B, et al. Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality? Eur Heart J Cardiovasc Pharmacother. 2015;1:220–228. doi: 10.1093/ehjcvp/pvv023.
    1. Arnold SV, Lipska KJ, Li Y, et al. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J. 2014;168:466–470.e1. doi: 10.1016/j.ahj.2014.06.023.
    1. Kim EJ, Jeong MH, Kim JH, et al. Clinical impact of admission hyperglycemia on in-hospital mortality in acute myocardial infarction patients. Int J Cardiol. 2017;236:9–15. doi: 10.1016/j.ijcard.2017.01.095.
    1. Grant PJ, Cosentino F. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen. Eur Heart J. 2019;40:3215–3217. doi: 10.1093/eurheartj/ehz687.
    1. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65. doi: 10.1016/0735-1097(95)00126-K.
    1. Malmberg K, Rydén L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–661. doi: 10.1093/eurheartj/ehi199.
    1. Alabas OA, Hall M, Dondo TB, et al. Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study. J Epidemiol Community Health. 2017;71:25–32. doi: 10.1136/jech-2016-207402.
    1. Choo EH, Chang K, Lee KY, et al. Prognosis and predictors of mortality in patients suffering myocardial infarction with non-obstructive coronary arteries. J Am Heart Assoc. 2019;8:e011990. doi: 10.1161/JAHA.119.011990.
    1. Nordenskjöld AM, Baron T, Eggers KM, Jernberg T, Lindahl B. Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. Int J Cardiol. 2018;261:18–23. doi: 10.1016/j.ijcard.2018.03.056.
    1. Pizzi C, Xhyheri B, Costa GM, et al. Nonobstructive versus obstructive coronary artery disease in acute coronary syndrome: a meta-analysis. J Am Heart Assoc. 2016;5:e004185. doi: 10.1161/JAHA.116.004185.
    1. Paolisso P, Bergamaschi L, Saturi G, et al. Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease. Front Pharmacol. 2019;10:1606. doi: 10.3389/fphar.2019.01606.
    1. Montone RA, Niccoli G, Lanza GA, Crea F. Personalized treatment of myocardial infarction and non-obstructive coronary arteries: an unmet need in a high-risk population. Eur Heart J. 2018;39:3335. doi: 10.1093/eurheartj/ehy305.
    1. Crea F, Montone RA, Niccoli G. Myocardial infarction with non-obstructive coronary arteries: dealing with pears and apples. Eur Heart J. 2020;41:879–881.
    1. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA) Diabetes Care. 2005;28:2551–2553. doi: 10.2337/diacare.28.10.2551.
    1. Paolisso P, Foà A, Bergamaschi L, et al. Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA. Cardiovasc Diabetol. 2021;20:33. doi: 10.1186/s12933-021-01222-9.
    1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal definition of myocardial infarction (2018) Circulation. 2018;138:e618–e651. doi: 10.1161/CIR.0000000000000617.
    1. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–1367. doi: 10.1093/eurheartj/ehaa575.
    1. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38:143–153.
    1. Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139:e891–e908. doi: 10.1161/CIR.0000000000000670.
    1. Khalfallah M, Abdelmageed R, Elgendy E, Hafez YM. Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Diab Vasc Dis Res. 2020;17:1479164119883983. doi: 10.1177/1479164119883983.
    1. Kitano D, Takayama T, Nagashima K, et al. A comparative study of time-specific oxidative stress after acute myocardial infarction in patients with and without diabetes mellitus. BMC Cardiovasc Disord. 2016;16:102. doi: 10.1186/s12872-016-0259-6.
    1. D'Onofrio N, Sardu C, Paolisso P, et al. MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. J Cell Physiol. 2020;235:1438–1452. doi: 10.1002/jcp.29064.
    1. Angeli F, Reboldi G, Poltronieri C, et al. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. Ther Adv Cardiovasc Dis. 2015;9:412–424. doi: 10.1177/1753944715594528.
    1. Marik PE, Bellomo R. Stress hyperglycemia: an essential survival response! Crit Care Med. 2013;41:e93–e94. doi: 10.1097/CCM.0b013e318283d124.
    1. Sardu C, Barbieri M, Balestrieri ML, et al. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovasc Diabetol. 2018;17:152. doi: 10.1186/s12933-018-0795-8.
    1. Martínez MS, García A, Luzardo E, et al. Correction: Energetic metabolism in cardiomyocytes: molecular basis of heart ischemia and arrhythmogenesis. Vessel Plus. 2018;2:32. doi: 10.20517/2574-1209.2018.68.
    1. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271. doi: 10.1016/j.jacc.2013.02.092.
    1. Lee JF, Barrett-O'Keefe Z, Garten RS, et al. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart. 2016;102:278–284. doi: 10.1136/heartjnl-2015-308403.
    1. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003;10:113–126. doi: 10.1080/713773607.
    1. Sara JD, Taher R, Kolluri N, Vella A, Lerman LO, Lerman A. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. Cardiovasc Diabetol. 2019;18:22. doi: 10.1186/s12933-019-0833-1.
    1. Cho JY, Kim KH, Lee SE, et al. Admission hyperglycemia as a predictor of mortality in acute heart failure: comparison between the diabetics and non-diabetics. J Clin Med. 2020;9:149. doi: 10.3390/jcm9010149.
    1. Sardu C, Paolisso P, Sacra C, et al. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: The CODYCE Multicenter Prospective Study. Diabetes Care. 2019;42:1946–1955. doi: 10.2337/dc18-2356.

Source: PubMed

3
Se inscrever